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Abstract  
Purpose: The primary aim of this study was to measure the objective tumor response rate following treatment 
with indisulam [E7070; N-(3-chloro-7-indolyl)-1,4-benzenedisulfonamide] as second-line therapy in patients 
with advanced non-small cell lung cancer. The secondary aims were to determine progression-free survival, to 
assess the safety and tolerability of indisulam, and to study its pharmacokinetic and pharmacodynamic profile. 
Experimental Design: Patients were randomized to receive indisulam every 3 weeks either as a single i.v. dose 
of 700 mg/m2 on day one (dx1) or 130 mg/m2 given on days 1 to 5 inclusive as a daily infusion (dx5). All 
patients had previously received platinum-based chemotherapy. 
Results: Forty-four patients were randomized. Only minor responses were seen. Myelosuppression, 
gastrointestinal symptoms, and lethargy were the most common toxicities and were more frequent in the dx1 
arm. The pharmacokinetics of indisulam in each treatment schedule were adequately described using a 
previously developed population pharmacokinetic model and were mostly consistent with the results of the phase 
I program. Flow cytometric analysis of endobronchial and metastatic disease revealed a reduction in the fraction 
of cycling cells and an increase in apoptosis following indisulam compared with pretreatment levels.  
Conclusions: We conclude that, despite evidence of tumor-specific indisulam-induced apoptosis, neither of 
these treatment schedules has single-agent activity as second-line treatment of non -small cell lung cancer. 
 
 
Lung cancer is the leading cause of cancer death in the world and is associated with a 5-year survival of only 
15% (1). For non-small cell lung cancer (NSCLC), surgery is the only curative option for early-stage disease. 
However, the majority of patients present with advanced disease, for which treatment is palliative. First-line 
platinum-based chemotherapy results in significant, although modest, improvement in clinical outcome (2-4). 
Second- or third-line therapies prolong survival when compared with supportive care alone but have objective 
response rates of only 7% to 9% (5, 6). There is clearly a clinical need to develop effective second-line therapies 
that deliver improved response, survival, and toxicity profiles. 
Indisulam (E7070) is a chloroindolyl sulfonamide that has activity in a wide range of human tumor cell lines and 
the PC-9 lung cancer xenograft in mice (7). Structurally, indisulam is similar to chloroquinoxaline sulfonamide, 
an antiproliferative compound for which clinical development was discontinued because of cardiac dysrhythmias 
and hypoglycemia (7). The exact molecular target of indisulam remains to be defined. In human NSCLC cell 
lines, treatment with indisulam induced G1-S cell cycle arrest with up-regulation of p53 and p21 and subsequent 
apoptosis (8). Proteomic analysis suggests that indisulam may affect glucose metabolism and the malate-
aspartate shuttle by inhibition of cytosolic malate dehydrogenase, although the relationship between this and the 
effect of indisulam on the cell cycle are unclear (9). 
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Phase I studies confirmed that reversible neutropenia and thrombocytopenia were the dose-limiting toxicities of 
indisulam. Mucositis and fatigue were also observed (10-14). In view of the structural similarity of indisulam to 
other sulphonamide agents, serum glucose and electrocardiogram monitoring were included in this study. 
Preclinical models suggested that the anticancer activity of indisulam is schedule dependent. The two i.v. 
schedules selected for evaluation were one dose of 700 mg/m2 given on day one (dx1) or five doses of 130 
mg/m2 given on days 1 to 5 (dx5) repeated at three weekly intervals (11, 12). This multicenter randomized phase 
II study was done to explore the efficacy and toxicity of indisulam and to identify which schedule was more 
active in platinum pretreated NSCLC. Sequential endobronchial and metastatic tumor samples were taken to 
analyze the effects of indisulam on the cell cycle in vivo. 
Materials and Methods 
Patient selection. Patients over the age of 18 years with pathologically confirmed stage IIIB or IV NSCLC who 
had relapsed following or progressed during treatment with a first-line platinum containing chemotherapy 
regimen were included. Patients could not have received chemotherapy, radiotherapy (other than palliative 
radiotherapy to a nonmeasurable lesion), or investigational treatment within 4 weeks of study entry (or 6 weeks 
for nitrosoureas, mitomycin C, or melphalan). Criteria for inclusion were as follows: bidimensionally measurable 
disease outside a radiotherapy field, Karnofsky performance status of 70% or higher, life expectancy of >4 
months, adequate hematologic function (hemoglobin >9 g/dL, neutrophils >1.5 × 109/L, and platelets >100 × 
109/L), renal function (serum creatinine <1.5 × upper normal limit or creatinine clearance ≥60 mL/min), and 
hepatic function [serum bilirubin <25 µmol/L and alanine transaminase or aspartate transaminase ≤2.5 × upper 
normal limit (≤5 × upper normal limit in the presence of liver metastasis)]. Patients with central nervous system 
metastases, uncontrolled infection, cardiac dysfunction, or serious concomitant medical conditions were 
excluded. In view of possible drug interactions with indisulam, patients were excluded if they had received any 
of the following drugs within 2 weeks of enrollment: coumarin anticoagulants, terfenadine, cisapride, 
cyclosporin, tacrolimus, theophyllines, diazepam, sulfonylurea hypoglycemic agents, phenytoin, or 
carbamazepine. Patients were also excluded if they were pregnant or breast-feeding. Adequate contraception was 
required where appropriate. The study was given approval by local research ethics committees. All patients were 
required to give written informed consent. At one center (Oxford, United Kingdom), patients with endobronchial 
tumors who consented to two additional bronchoscopies for tumor sampling could be entered into a 
corresponding pharmacodynamic study. 
Study design and end points. This study was an open label, multicenter, randomized, comparative phase II study 
of indisulam administered by two different dosing regimens. The primary objective of the study was to measure 
the objective tumor response rate within each dosing regimen. The design of the study incorporated a single-
stage testing procedure as described by Gehan (15). With 44 patients randomized, the probability of the study 
leading to an erroneous rejection of the drug having a true second-line response rate of at least 10% is 0.098. 
Within each dosing regimen, the hypothesis that the true response rate is at least 10% would be rejected if there 
were fewer than 2 responses in 22 patients. 
Secondary objectives of the study were duration of response, progression-free survival, median survival, and the 
safety and tolerability of indisulam. The pharmacokinetics of each schedule of indisulam were evaluated from a 
previously described population model (16, 17). Treatment-related changes in cell cycle progression and 
apoptosis were assessed before and after treatment with indisulam in a subgroup of patients. 
Treatment plan. Patients were screened within 14 days of enrollment and randomized on a 1:1 basis to receive 
indisulam according to the dxl or dx5 schedule. Indisulam was administered i.v. over 60 min. Toxicity was 
evaluated weekly using the National Cancer Institute Common Toxicity Criteria, version 2. Treatment was 
delayed if the neutrophil count was ≤1 × 109/L or the platelets were ≤100 × 109/L on day 1 of treatment or until 
treatment-related toxicity had returned to baseline or ≤grade 2. A maximum delay of 2 weeks was permitted. A 
25% dose reduction was made to all subsequent cycles following grade 4 toxicity, except for anemia or 
lymphopenia. Serum glucose was measured before, at completion of, and 2.5 h after the first indisulam infusion. 
Tumor size was assessed by computed tomography or magnetic resonance imaging every two cycles, and 
response was documented using WHO criteria by independent review. Treatment was continued until disease 
progression or unacceptable toxicity. 
Pharmacokinetics. Pharmacokinetics were evaluated in all patients during the first three cycles of treatment. 
Sampling time points were identified from an established population pharmacokinetics model using the D-
optimality algorithm (16, 17). For the dxl regimen, a total of six blood samples were collected: predose; at the 
end of infusion; and 2.5, 7, 94, and 168 h after the start of infusion. For the dx5 regimen, a total of six blood 
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samples were collected: predose on days 1 and 5; at the end of the infusion and 1.5 h after the start of infusion on 
day 5; and 72 and 168 h after the start of the fifth infusion. The concentration of indisulam was determined in 
plasma as described previously (16). 
Pharmacokinetic analyses were done using NONMEM software (version V, level 1.1; GloboMax LLC, Hanover, 
MD). The population model described previously (16) comprises three compartments with saturable distribution 
to one of the peripheral compartments and a linear and saturable pathway of elimination from the central 
compartment shown in Fig. 1. The pharmacokinetic variables describing this model were reestimated using the 
data obtained from this study in combination with the pharmacokinetic data from the phase I program. To 
establish whether pharmacokinetic variables differed significandy, a covariate indicating that data were obtained 
from this study was evaluated for each pharmacokinetic variable. Data were logarithmically transformed and 
analyzed using the first-order method. Individual Bayesian pharmacokinetic variables were calculated using the 
post hoc option in NONMEM. 
 
Fig. 1.   Population pharmacokinetic model for indisulam. The model comprises three compartments (central, 
periph.1, and periph.2) with saturable distribution to one of the peripheral compartments and a linear and 
saturable pathway of elimination from the central compartment. V, central volume of distribution; Tmax, maximal 
distribution rate; Tm, Michaelis Menten constant of distribution; k21, distribution rate constant periph.1 > 
central; k13, distribution rate constant central > periph.2; k31, distribution rate constant periph.2 > central; 
Km, Michaelis Menten constant of elimination; Vmax, maximal elimination rate; k10, elimination rate constant. 
 
 
Pharmacodynamic studies. Cells from bronchial brushings and washings were collected from 14 untreated 
patients with NSCLC as a control group and from three patients before and 48 h after indisulam treatment. 
Samples were taken from the endobronchial tumor and from the contralateral bronchus as controls. Samples 
were centrifuged and washed in PBS. For accessible soft-tissue metastasis, fresh core biopsy and fine-needle 
aspiration samples were disaggregated in PBS, trypsin, and collagenase before fixation. Cell pellets were fixed in 
cold ethanol, washed, and resuspended in PBS containing propidium iodide and RNase A. Samples were 
analyzed by flow cytometry (FACSCalibur, Becton Dickinson, San Jose, CA) using a 488 nm laser for 
excitation. Red fluorescence data, indicative for DNA content, were collected for up to 10,000 cells per sample 
and analyzed using CellQuest software (Becton Dickinson). A gate was set using forward light scatter to exclude 
subcellular fragments, and the proportion of cells undergoing apoptosis in each sample was estimated by 
quantification of cells with an apparent DNA content less than that of diploid cells in G1. This value was 
determined by reference to the sample from the unaffected bronchus. 
Results 
Forty-four patients from eight centers were entered into the study (23 to the dx1 schedule and 21 to the dx5 
schedule). Patient characteristics are shown in Table 1. The groups were well balanced with respect to age, stage, 
gender, and performance status. Twenty-one (48%) patients had responded to previous platinum-based 
chemotherapy and 9 (20%) patients had progressed during prior treatment. Patients received a median number of 
two cycles on the dxl schedule (range, 1-10) and two cycles on the dx5 (range, 1-4). 
 
Toxicity. Eight patients experienced treatment-related serious adverse events (seven on the dx1 schedule and one 
on the dx5 schedule). In general, adverse events were more common among patients receiving the dx1 schedule. 
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Two patients withdrew from the study as a result of adverse events. One patient (dxl schedule) had a 
combination of asthenia, herpetic stomatitis, and anemia. The second patient (dx5 schedule) developed seizures 
due to cerebral metastases. Three patients on the dx1 arm and two patients on the dx5 arm had dose reductions 
based on grade 4 toxicity. The most common grade 1-2 toxicities were nausea, vomiting, constipation, diarrhea, 
asthenia, and injection site reactions. Eight patients on the dxl schedule had an increase in serum bilirubin 
immediately following treatment with indisulam, of whom two experienced grade 3 hyperbilirubinemia. In all 
but one case, hyperbilirubinemia was transient,   occurred   ~2.5 h  after indisulam administration, was not 
accompanied by elevations in other liver function tests, and had resolved by day 8. There were no episodes of 
tachyarrhythmia or hypoglycemia (blood sugar ≤3 mmol/L), although three cases of grade 3 hyperglycemia were 
seen. Data on grade 3 and 4 toxicity are presented in Table 2. 
Response and survival. Only minor responses were seen on independent radiological review. The best response 
to treatment based on WHO criteria were as follows: (a) dx1 schedule: stable disease 8 (36%) and progressive 
disease 14 (64%) and (b) dx5 schedule: stable disease 5 (23%) and progressive disease 17 (77%). Two patients 
treated on the dx1 schedule had disease stabilization for >12 weeks (5.7 and 6.2 months). Survival at 6 months 
was 45% for patients on dx1 and 29% on the dx5 schedule. Kaplan-Meier estimates of progression-free and 
overall survival are presented in Figs. 2 and 3, respectively 
 
Table 1. Patient characteristics 
Schedule dx1 dx5 
Males 18 (78%) 17 (81%) 
Females 5 (22%) 4 (19%) 
Median age (range), y 58 (35-76) 61 (44-74) 
Karnofsky performance status 80 (70-100) 80 (70-100) 
Median (range)   
   70-80% 12 (55%) 11 (52%) 
   90-100% 10 (45%) 10 (48%) 
NSCLC stage IIIB 10 (45%) 10 (48%) 
   stage IV 12 (55%) 11 (52%) 
 
 
Table 2. Grade 3 and 4 toxicities 
Schedule dx1 (%) dx5 (%) 
Hematologic toxicity   
   Neutropenia 5 (23) 0 
   Thrombocytopenia 4 (18) 0 
   Febrile neutropenia 1 (5) 0 
   Anemia 4 (18) 1 (5) 
Biochemical toxicity   
   Hyperbilirubinemia 2 (9) 0 
   Hyponatremia 7 (32) 0 
   Hypokalemia 1 (5) 0 
   Hyperkalemia 1 (5) 0 
   Raised γ-glutamyl transferase 4 (18) 3 (14) 
   Hypoalbuminemia 2 (9) 0 
   Hyperuricemia 2 (9) 0 
Other toxicity   
   Fatigue/lethargy 2 (9) 2 (9) 
   Asthenia 2 (9) 1 (5) 
   Injection site reaction 1 (5) 0 
   Mucositis 2 (9) 0 
   Hemorrhagic stroke 1 (5) 0 
   Pulmonary septic syndrome 1 (5) 0 
   Candidiasis 1 (5) 0 
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Fig. 2. Progression-free survival. Kaplan Meier plot of progression-free survival following indisulam given as a 
daily × 1 schedule (—) or as a daily × 5 schedule (----------). 
 
 
Fig. 3.  Overall survival. Kaplan Meier plot of overall survival following indisulam given as a daily × 1 
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Table 3. Summary of estimated pharmacokinetic variables 
PK variable Variable estimate Interindividual 
variability (%) 
V (L) 7.3 26 
Tmax (mg/h) 25.7 43 
Tm (mg/L) 2.18 127 
k21 (h-1) 0.0735 60 
k13 (h-1) 0.889* 31 
 0.607†  
k31 (h-1) 0.387 20 
km (mg/L) 0.712 61 
V max (mg/h) 3.39 130 
k10 (h-1) 0.0241 26 
Abbreviation: PK, pharmacokinetic.  
*Phase I.  
†Current study. 
 
Pharmacokinetics. Data from all patients were included in the analysis. Variable estimates for this study were 
not significantly different from those of the phase I studies, except for the value of k13, which was ~32% lower 
(Table 3). For a typical individual with a body surface area of 1.8 m2, this would result in a 19% and 16% 
increase in drug exposure for patients receiving the dx1 and dx5 schedule, respectively. Plasma concentration 
versus time profiles for individual patients treated with the dx1 and the dx5 schedule are depicted in Fig. 4. In 
Fig. 5, the model predicted and the individual predicted concentrations are plotted against the observed plasma 
concentrations. The symmetrical distribution around the line of identity indicates that the population 
pharmacokinetic model adequately describes the pharmacokinetic profile of indisulam in both treatment 
schedules. Median area under the concentration time curve was 2.9 × 103 h mg/L (interquartile range, 1.9 × 103-
3.4 × 103 h mg/L) and 1.8 × 103 h mg/L (1.0 × 103-2.2 × 103 h mg/L) for the dx1 and dx5 schedules, 
respectively. 
Pharmacodγnamic studies. Data from control patients who did not receive indisulam showed that NSCLC cells 
in vivo exhibit a large variability in >G1 (aneuploidy or active cycling) compared with the contralateral 
unaffected lung (Table 4). In some endobronchial tumor samples, an aneuploid tumor population was clearly 
evident and distinguishable from the diploid epithelial component based on its increased DNA content. There 
was also a trend toward a higher proportion of <G1 (apoptotic) cells in the affected lung, although the difference 
was not statistically significant. Three patients consented to flow cytometric analysis before and after indisulam 
treatment. Of these, two patients had bronchial brushings and washings and one patient had fine-needle 
aspiration and biopsy of a cytologically confirmed 3 cm diameter subcutaneous metastasis. Following treatment 
with indisulam, endobronchial tumor cells showed a large decrease in the >G1 fraction and an increase in the <G1 
apoptotic fraction (Fig. 6). Fine-needle aspiration of the metastasis yielded insufficient tissue for flow cytometry. 
However, cells derived from core biopsies could be analyzed by flow cytometry. This showed that s.c. 
metastases had a low proportion of normal diploid cells and high levels of presumably apoptotic cells present 
before treatment. The apoptotic fraction of tumor cells in metastatic deposits increased substantially 48 h after 
indisulam treatment. A substantial decrease in the >G1 fraction was also noted. All three patients had stable 
disease on radiological response criteria. 
 
Table 4. Flow cytometry of bronchial  washings and bronchial brushings 
Tissue sample Mean <G1, % (range) Mean >G1, % (range) 
BW-normal 5.9 (1.65-18.17) 9.3 (3.47-16.89) 
BW-tumor 11.1 (1.87-24.99) 13.0 (5.37-37.73) 
BB-normal 4.6 (0.84-8.1) 12.9 (4.01-17.28) 
BB-tumor 9.2 (3.44-19.67) 29.0 (11.98-66.75) 
Abbreviations: BW, bronchial washings; BB, bronchial brushings; tumor, samples from endobronchial tumor; normal, samples from 
contralateral, unaffected bronchus. 
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Fig. 4. Indisulam plasma concentration versus time profiles for individual patients (♦) and the profile predicted 
(16) by the population pharmacokinetic model (—). A, daily × 1 schedule. B, daily × 5 schedule. 
 
 
Fig. 5.  Goodness-of-fit plots of the population pharmacokinetic data. Model predicted concentrations (A) and 
individual predicted concentrations (B) are plotted against the observed values for all treatment cycles and for 
both regimens. The symmetrical distribution around the line of unity indicates that these data are adequately 
described by the model. 
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Fig. 6.   Flow cytometry of tumor cells before, and following, indisulam treatment. Distribution of cellular DNA: 
<G1 (apoptotic); G1 (normal diploid); and >G1 (aneuploid or active cycling). A and B, endobronchial tumor 
cells pretreatment (top) and following indisulam (bottom) for two individual patients. C, biopsy from soft tissue 




The results of this study suggest that indisulam as a single agent at the doses and schedules investigated has 
limited ability to induce objective responses for patients with NSCLC treated previously with platinum-based 
chemotherapy. Although several patients experienced a reduction in the volume of their disease, this was usually 
transient and benefit was short lived. Disease stabilization beyond 5 months was observed in two patients 
receiving the dx1 schedule. The low response rate is consistent with other agents used in second-line therapy          
(5, 6). In general, treatment was well tolerated. Two patients withdrew from the study as a result of adverse 
events. These were more common on the dx1 schedule, although as only five patients on the dx5 schedule 
received more than two courses, this may reflect the number of courses administered. Myelosuppression was 
moderate with 23% of patients experiencing grade 3 or 4 neutropenia. One patient died during an episode of 
neutropenic sepsis. Although transient episodes of hypoglycemia were noted during the phase I program, 
hypoglycemia and arrhythmias were not a feature of indisulam therapy in this study. The dx1 schedule was 
associated with mild injection site reactions, which were less pronounced when indisulam was made up in 1,000 
mL, rather than 500 mL, of saline. Several biochemical abnormalities were recorded, particularly hyponatremia. 
This may have been due to NSCLC, a worsening nutritional state or indisulam-induced inhibition of specific 
carbonic anhydrase isoenzymes, including those in the kidney (18). 
The pharmacokinetic profile of indisulam was adequately described by the previously developed and validated 
population pharmacokinetic model (16). Although the value of the microconstant k13 was ~32% lower in this 
study compared with the value obtained from the phase I studies, the relevance of this finding is difficult to 
interpret. The data from this study were sparsely sampled; therefore, it is difficult to establish distribution 
microconstants with high precision. However, the reduction in k13 was significant and has a clinically relevant 
effect on the overall exposure to indisulam. Nonetheless, these effects were minimal compared with the large 
interpatient variability in exposure. 
We believe that this is the first study to report flow cytometry of serial endobronchial tumor samples in NSCLC. 
This study suggests that bronchial brushings are more sensitive than bronchial washings as an indicator of drug 
effect. There was considerable overlap in terms of the results from bronchial washings taken from healthy 
control lung and the tumor-affected lung. The proportions of cycling and apoptotic cells were markedly different 
between primary bronchial samples and metastatic tumor. Tumor samples from three patients obtained pre-
indisulam and post-indisulam showed an increase in <G1 fraction and a reduction in >G1 cycling (aneuploid) 
fraction. This was not accompanied by a decrease in radiological size of the tumors. One possible explanation for 
this apparent discrepancy may be that these changes are transient and were not maintained long enough 
following treatment to produce tumor response.  Due to the limited amount of material available, the only 
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criterion used for the assessment of apoptosis in these samples was the measurement of sub-G1 DNA content. 
Use of phospho-specific anti-retinoblastoma antibodies to evaluate phosphorylated retinoblastoma in patients 
with head and neck cancer treated with indisulam has been reported (19). Three of five patients had informative 
results where a reduction in posttreatment retinoblastoma phosphorylation occurred. As in our study, this 
pharmacodynamic end point did not correlate with clinical tumor response. Apparently, lack of persistence in the 
pharmacodynamic effect may account for the absence of relationship to clinical outcome. 
Although no objective responses to indisulam were documented in this setting, this study has provided valuable 
information about the effects on the cell cycle of indisulam in vivo. It also shows that it is possible to use flow 
cytometry of bronchial brushings from NSCLC patients to monitor the effect of novel therapies on the cell cycle. 
Further phase II studies of indisulam in a range of tumor types as a single agent and in combination with other 
therapies are ongoing. No further exploration of the dx5 schedule is planned. 
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